Evaluating Combined Supraorbital and Occipital Neuromodulation in Resistant Migraine Trial: The RECLAIM Study
Salvia BioElectronics’ PRIMUS system, currently being assessed in a clinical trial, delivers subcutaneous occipital and supraorbital nerve stimulation for patients with resistant migraine.
Resistant migraine is characterized by at least 8 monthly days of disabling headache and inadequate response, intolerance, or contraindication to 3 or more classes of preventive therapies. This condition primarily results from treatment failures rather than complex underlying mechanisms, and those with it may benefit from migraine-specific preventive medications. Neuromodulation represents a potential preventive treatment approach and has been shown in studies to reduce migraine days in patients with refractory migraine, a related but mechanistically distinct subgroup.1